Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So, 9% to 13% reported organically is mid-single digits, and we feel like that's a spot that we're highly confident we can execute against multiple different scenarios or outcomes there |
| QSP is at the cutting edge of biosimulation approaches and has vast potential to improve the biopharmaceutical R&D and informed decision-making across the drug development process |
| We are pleased to finish the year with a solid fourth quarter performance in both software and in technology-enabled services |
| And as we look forward, we're feeling very encouraged by the progress and the possibilities of what we can do with our products going forward and that's reflected in that revaluation |
| We had record software sales in the fourth quarter and we were encouraged to see our technology-enabled services bookings pick up in the second half of 2023 |
| I am confident that the secular adoption of biosimulation, our improved commercial execution and the investments we are making in our products and our team, will support strong growth in 2024 and beyond |
| As far as the second part of the question, then, we saw Tier 1 performance due solid -- stepping up from Q3 into Q4, we saw Tier 1s perform very well in both software and in services |
| As I mentioned earlier, we saw a really strong Tier 1 performance in our customers in software and actually across the tiers for software as we exited the year on bookings |
| And when we see those types of things, I think it's really good that we have the ability and the track record of moving successfully to integrate them into Certara |
| During the second half of 2023, we reorganized our commercial infrastructure to better sell our end-to-end solutions and the team delivered improved results in both software and services throughout the second half |
| With our new enterprise sales approach, we have effectively captured cross-selling opportunities, leading to expanded relationships with some of our top customers |
| I am very happy with the progress our team has made so far, and I'm confident that these improvements will support our commercial initiatives in the coming years |
| The growth opportunity in biosimulation continues to strengthen as drug developers look to maximize capital efficiencies and reduce pipeline risk |
| So, we've been fortunate to have a history of a fair number of very successful bolt-on acquisitions to help us create the company |
| The fourth quarter revenue growth of 15% and full year revenue growth of 14% represent healthy performance and contribution from new customers |
| So, we wouldn't break out really by platform, what that looks like, but 15% software growth, 14% on the year, is a good spot for us to be |
| Customer feedback on our AI products has been encouraging and drove customer interest in the second half of the year |
| So, that momentum is a solid point for us |
| We believe we are the employee of choice in the biosimulation industry and we offer a strong culture and commitment to innovation |
| I am confident that these investments will create new opportunities to grow our platform on a global scale and penetrate deeper into our customers' R&D organizations |
| We had a very strong Q4 software revenue performance, up 15% and on a full year performance, up 14%, despite our ARR being in the mid-80s in the second half of the year and 88% for the full year |
| Thus far, we are pleased with the improved execution in the services business, which is performing better as a combined organization |
| Across our technology-enabled services group, we saw a pickup in new business activity, which led to sequential bookings growth in the fourth quarter |
| So, we're pleased with the progress, and it's one of the key areas for investment |
| We have a strong base of business in Europe |
| Trailing 12-month software bookings were $136.9 million, also up 10% year-over-year |
| We've been very pleased with the integration of Vyasa into Certara |
| The signs of -- the positive signs, though, that you heard us talking about were mainly centered in bookings, and came in Q4 where we had said that business is marked by often having large deal bookings come in, in Q4, and we saw that happen |
| Our technology-enabled services business overcame market headwinds to deliver solid performance in the second half of 2023 |
| We did benefit in the fourth quarter, I think, from a pick up a bit in the end markets, and then I think there were quite a number of big customers that had budgets during the year |
| Statement |
|---|
| TTM services bookings were $265.4 million, also down 7% as compared to the prior year |
| Bookings, which provides visibility into the year ahead, came in at $402.3 million for the trailing 12-month period ended December 31st, 2023, down 2% year-over-year |
| which was $54.4 million in the fourth quarter, down 5% versus the prior year on a reported basis and down 6% on a constant currency basis |
| 2023 presented our industry with many challenges as pharmaceutical and biotech customers were conservative in their spending amidst macroeconomic and geopolitical pressures |
| That bookings number is down a couple of percent |
| Technology-driven services bookings in the fourth quarter were $75.6 million, which decreased 7% from the prior year period |
| Just picking up on guidance, it looks like your adjusted EBITDA margin outlook for 2024 is a little light considering the sales growth that you're expecting plus where you finish 2023 |
| Net loss for the fourth quarter of 2023 was $12.5 million compared to net income of $9.2 million in the fourth quarter of 2022 |
| The second point is just around the backlog conversion that we experienced during 2023 when some of the bookings conversion was slowing down, has a trickle over effect into 2024 |
| I'd say that investment in the sales training and just uniting the sales force is probably not fully realized yet |
Please consider a small donation if you think this website provides you with relevant information